赛乐医药科技

Sela Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets in oncology and immunology, leveraging its proprietary drug discovery platform to create highly selective inhibitors. Its lead programs include SL-001, a next-generation BTK inhibitor, and SL-101, a JAK1 inhibitor, both aimed at addressing unmet needs in hematological malignancies and autoimmune disorders. Sela Pharma aims to provide more effective and safer treatment options through precision medicine. The company is supported by prominent venture capital firms, including Matrix Partners China and Qiming Venture Partners. With a robust pipeline and internal R&D capabilities, Sela Pharma is positioned to advance novel treatments for patients globally.